Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept & continue
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Leading economies at risk of falling into high-inflation trap, BIS says
    • G7 aims to hurt Russia with price cap on oil exports
    • Overturning of Roe vs Wade sets out rightwing path for US Supreme Court
    • Boris Johnson pledges to stay in power until the 2030s
    • European energy crisis reignites debate over closure of Groningen reserve
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Overturning of Roe vs Wade sets out rightwing path for US Supreme Court
    • A devastating blow to women’s rights in America
    • Grim times lie ahead for UK as inflation combines with low growth
    • Abortion battle shifts to US Congress and midterm elections
    • History says US stock market has further to fall
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Time is ripe to snap up bargains, says debt investor Howard Marks
    • UK’s local builders disappearing in their thousands as costs soar
    • Rising rates raise prospect of property crash
    • BioNTech/Pfizer say Omicron-targeting boosters elicit strong immune response
    • Centrica pulls out of Bulb auction in blow to government
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    • Cryptocurrencies
    Most Read
    • Time is ripe to snap up bargains, says debt investor Howard Marks
    • History says US stock market has further to fall
    • Investors are on recession watch
    • Stocks snap weekly losing streak on scaled back rate-rise expectations
    • Did the Fed’s preferred measure of inflation cool in May?
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
    Most Read
    • If you want to be more likeable, try showing more stress
    • A devastating blow to women’s rights in America
    • Grim times lie ahead for UK as inflation combines with low growth
    • Global financial centres: where hustle’s the name of the game
    • Who is worse company, the left or the right?
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • If you want to be more likeable, try showing more stress
    • JSR’s Eric Johnson: ‘I encourage people to tell me exactly how they think’
    • Humour in the office matters, but can a boss be funny?
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • Inside the secret, often bizarre world that decides what porn you see
    • Best summer books of 2022: Critics’ picks
    • Writer Vladimir Sorokin: ‘I underestimated the power of Putin’s madness’
    • Who is worse company, the left or the right?
    • Abortion in America — the road to rolling back Roe vs Wade
  • HTSI
MenuSearch
  • Home
  • World
  • US
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Work & Careers
  • Life & Arts
  • HTSI
Financial Times
SubscribeSign In

Your guide to a disrupted world

Start a 4-week trial

Biogen Inc

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Wednesday, 4 May, 2022
    FT News Briefing podcast8 min listen
    Draghi urges EU to abandon unanimity requirement

    Biogen chief to step down after the company’s Alzheimer’s drug flops

  • Tuesday, 3 May, 2022
    Biogen chief to step down after Alzheimer’s drug flops

    US biotech to dismantle sales infrastructure for treatment as it begins search for successor

  • Sunday, 17 April, 2022
    Anjana Ahuja
    Hasty approval for Alzheimer’s drug offers a cautionary tale

    FDA’s green light for aducanumab may delay development of more effective treatments for dementia, critics say

  • Monday, 20 December, 2021
    Biogen halves price of Alzheimer’s drug after sales fall short

    Insurers’ reluctance to pay for Aduhelm treatment forces biotech to lower costs as EMA highlights safety concerns

  • Wednesday, 17 November, 2021
    European regulators cast doubt on Biogen Alzheimer’s drug

    Vote by European Medicines Agency panel deals setback to controversial $56,000-a-year treatment

  • Wednesday, 20 October, 2021
    Biogen sells just $300,000 worth of contentious Alzheimer’s drug

    Third-quarter revenues from $56,000-per-year treatment were well below analysts’ expectation of $10m

  • Thursday, 22 July, 2021
    Biogen defends contentious $56,000 Alzheimer’s drug

    Pharma group blames ‘misinformation’ for overshadowing approval of therapy

  • Friday, 9 July, 2021
    US Food & Drug Administration
    FDA calls for probe of staff involved in divisive Alzheimer’s approval

    US drugs watchdog was under pressure after scientific outcry over controversial Biogen treatment

  • Monday, 5 July, 2021
    News in-depthPharmaceuticals sector
    Approval of Biogen Alzheimer’s drug reignites ‘amyloid’ debate

    Hypothesis that brain plaques cause disease viewed with scepticism by some scientists

  • Wednesday, 16 June, 2021
    Pharmaceuticals sector
    Biogen’s Japanese partner calls for global action on Alzheimer’s

    Eisai says framework for testing and treatment urgently needed in response to ‘secret pandemic’

  • Friday, 11 June, 2021
    The Big Read
    The Alzheimer’s economy: is the new $56,000-a-year drug worth it?

    US approval of the Biogen treatment has given patients hope. But some experts worry expectations have been raised too high

  • Tuesday, 8 June, 2021
    The FT ViewThe editorial board
    How to make the most of the Alzheimer’s drug approval

    FDA decision on aducanumab must bring benefits beyond Biogen’s bottom line

  • Tuesday, 8 June, 2021
    Lex
    Biogen/Alzheimer’s: the high cost of hope Premium content

    Lofty prices reward risky, expensive research. But aducanumab’s pricing will raise eyebrows

  • Tuesday, 8 June, 2021
    Drug prices
    Biogen’s $56,000-a-year Alzheimer’s drug reignites US debate over costs

    Campaigners hit out at high price for controversial treatment that has divided scientists

  • Monday, 7 June, 2021
    Pharmaceuticals sector
    Alzheimer’s drug from Biogen wins US approval

    FDA signs off on first new treatment for disease in almost 20 years despite controversy over efficacy

  • Monday, 7 June, 2021
    Q&ADrugs research
    Alzheimer’s sufferers await ruling on potential blockbuster drug

    Biogen’s aducanumab would be first new treatment in years for disease if approved by FDA

  • Friday, 6 November, 2020
    Biogen Alzheimer’s drug in doubt after criticism from expert panel

    Scientists express scepticism of trial data and US regulatory process at fiery hearing

  • Wednesday, 4 November, 2020
    Biogen shares leap after ‘substantial evidence’ Alzheimer’s drug is effective

    FDA staff give positive clinical review to what could be first new treatment in US for decades

  • Monday, 10 February, 2020
    Drugs research
    Roche and Eli Lilly drugs fail ‘inherited’ Alzheimer’s trial

    Setback deals another blow to most common hypothesis about causes of the disease

  • Wednesday, 5 February, 2020
    Biogen shares soar after patent victory

    Mylan had lodged dispute over a drug for multiple sclerosis

  • Thursday, 5 December, 2019
    Dementia
    Biogen divulges more data on trials for Alzheimer’s drug

    Biotech’s shares fluctuate as it tries to win over sceptics of aducanumab

  • Wednesday, 23 October, 2019
    News in-depth
    Alzheimer’s drug revival gives hope to millions — and investors

    Biogen says seeking approval for aducanumab hails ‘turning point’ in fight against disease

  • Tuesday, 22 October, 2019
    Biogen shares soar on plan to seek Alzheimer’s drug approval

    Biotech group says new analysis shows benefits of aducanumab when taken at a high dose

  • Tuesday, 23 July, 2019
    Biotech group Biogen boosted by sales of key drugs

    Treatments for multiple sclerosis and spinal muscular atrophy help Biogen beat forecasts

  • Wednesday, 24 April, 2019
    Biotech
    Biogen promises to plug pipeline gap after Alzheimer’s failure

    Drug company’s chief Michel Vounatsos says it has the cash for share buybacks and M&A

Previous page You are on page 1 Next page

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT TransactSecondary Schools

Tools

PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

Community & Events

FT CommunityFT LiveFT ForumsFT Board DirectorBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2022. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

International Edition

Subscribe for full access
  • Switch to UK Edition
  • Top sections
  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
  • US
    • US Economy
    • US Companies
    • US Politics & Policy
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    • Cryptocurrencies
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • HTSI
  • Special Reports
  • FT recommends
  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • FTfm
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Community
    • FT Live
    • FT Forums
    • Board Director Programme
  • myFT
  • Portfolio
  • Today's Newspaper (ePaper)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In